{"product_id":"nsj-v9418-20ug-20ug","title":"CHRAC17 Antibody \/ POLE3, 20 ug","description":"\u003cp\u003eDNA replication is initiated by the binding of initiation factors to the origin of replication. Nucleosomes inhibit access to the replication machinery at these origin sequences. Nucleosome remodeling factors increase the accessibility of nucleosomal DNA to transcriptional regulators. CHRAC15 and CHRAC17 are subunits of the nucleosomal remodeling factor CHRAC (chromatin accessibility complex), which increases the accessibility of nucleosomal DNA in an ATP-dependent manner. Unlike other known chromatin remodeling factors, CHRAC also functions during chromatin assembly by using ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. This conversion process occurs when CHRAC organizes randomly deposited histones into a regularly spaced array. In the presence of CHRAC, the nucleosomal ATPase ISWI catalyzes several ATP-dependent transitions of chromatin structure.\u003c\/p\u003e\u003ch3\u003eSpecifications\u003c\/h3\u003e\u003ctable style=\"width:100%; border-collapse:collapse;\"\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eCatalog No\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eV9418-20UG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFamily\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePrimary antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eQty\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e20 ug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFormulation\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced), 0.05% sodium azide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eFormat\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePurified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eClone\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003ePCRP-POLE3-3D3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eHost Animal\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eMouse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eClonality\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eMonoclonal (mouse origin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eIsotype\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eMouse IgG2a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eSpecies Reactivity\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eELISA, FACS, IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication Details\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eELISA (order BSA-free format for coating),Flow cytometry: 1-2ug\/million cells,Immunofluorescence: 1-2ug\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eApplication Note\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eOptimal dilution of the CHRAC17 antibody should be determined by the researcher.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eLocalization\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eNucleus, Cytoplasm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eImmunogen\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eRecombinant full-length human POLE3 protein was used as the immunogen for the CHRAC17 antibody.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003ePurity\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eProtein A\/G affinity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eStorage\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eAliquot the CHRAC17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eLimitation\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eThis CHRAC17 antibody is available for research use only.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eUniprot #\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eQ9NRF9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eStatus\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eAvailable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003ePDF Link\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003e\u003ca href=\"https:\/\/www.nsjbio.com\/tds-pdf\/chrac17-antibody-pole3-pcrp-pole3-3d3-v9418\" target=\"_blank\" rel=\"noopener noreferrer\"\u003ehttps:\/\/www.nsjbio.com\/tds-pdf\/chrac17-antibody-pole3-pcrp-pole3-3d3-v9418\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eTitle\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eCHRAC17 Antibody \/ POLE3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth style=\"text-align:left; vertical-align:top; padding:6px; border-bottom:1px solid #eee;\"\u003eDescription\u003c\/th\u003e\n\u003ctd style=\"padding:6px; border-bottom:1px solid #eee;\"\u003eDNA replication is initiated by the binding of initiation factors to the origin of replication. Nucleosomes inhibit access to the replication machinery at these origin sequences. Nucleosome remodeling factors increase the accessibility of nucleosomal DNA to transcriptional regulators. CHRAC15 and CHRAC17 are subunits of the nucleosomal remodeling factor CHRAC (chromatin accessibility complex), which increases the accessibility of nucleosomal DNA in an ATP-dependent manner. Unlike other known chromatin remodeling factors, CHRAC also functions during chromatin assembly by using ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. This conversion process occurs when CHRAC organizes randomly deposited histones into a regularly spaced array. In the presence of CHRAC, the nucleosomal ATPase ISWI catalyzes several ATP-dependent transitions of chromatin structure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"NSJ Bioreagents","offers":[{"title":"20 ug","offer_id":51544884216088,"sku":"V9418-20UG","price":259.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/files\/get_image_835f588c-7acc-4194-bf14-800edcc8f14a.jpg?v=1768193467","url":"https:\/\/danabiosci.com\/products\/nsj-v9418-20ug-20ug","provider":"Dana Bioscience","version":"1.0","type":"link"}